ABSTRACT
INTRODUCTION
Hepatic steatosis refers to large vacuoles of triglyceride fat that accumulate in liver cells, including in alcoholic and non-alcoholic fatty liver disease. 1 Other causes of steatosis include hepatitis B and C infection. Nonalcoholic fatty liver disease can range from simple steatosis to steatohepatitis, and can subsequently progress to cirrhosis or hepatocellular carcinoma. Thus, evaluation methods for hepatic steatosis are of paramount importance to assess the suitability of donor livers before transplantation to reduce the high incidence of primary non-function. Currently, liver biopsy is the standard reference for steatosis assessment, but there are limitations such as procedure-related complications and high sampling variability.
1-3
In terms of non-invasive and accurate radiological diagnostic value, magnetic resonance imaging (MRI) and MR spectroscopy (MRS) have become acceptable and promising methods for assessment of steatosis. 2, 3 However, MRS is not suitable for routine clinical practice as it is time-consuming and requires specialised software and clinical expertise. 4 Currently, the chemical shift-based technique is one of the non-invasive MRI techniques for quantitative assessment of hepatic steatosis. The major limitation of the conventional chemical shift-based technique called 'dual phase' is that it is unable to evaluate the complete dynamic range of 0% to 100% fat fraction, even in patients with hepatic fat fraction (HFF) approaching 50%, and is limited to evaluating patients with severe steatosis. 2, 4 Therefore, the modified chemical shift-based technique known as the Dixon method has been adjusted to evaluate hepatic steatosis. The technique is widely available and easy to perform. Nevertheless, the accuracy of the Dixon method for quantification of hepatic steatosis can be affected by acquisition parameters. 5, 6 Based on a number of acquired images of the Dixon technique, the multipoint method tends to be less vulnerable to reconstruction errors than the two-point method, although in clinical practice, with critical acquisition times, the two-point method is more desirable. The multiecho two-point Dixon (mDixon) technique with flexible echo times has been shown to improve fat-water separation, have better signal-tonoise ratio, and have the feasibility of breath-hold. 7, 8 To our knowledge, there is limited documentation of semiquantitative assessment of hepatic steatosis with the mDixon technique using histopathological results as a standard reference. This study aimed to determine the use of the mDixon technique in the semi-quantification of hepatic fat in patients with chronic liver disease and to compare these results with the histopathology results.
METHODS

Study Population
From June 2012 to May 2013, patients with chronic liver disease who had indications for liver biopsy were recruited from the Hepatology Outpatients Clinic at Siriraj Hospital, Bangkok, Thailand. Patients who underwent liver MRI for evaluation of the severity of hepatic fibrosis and hepatic fat before undergoing liver biopsy on the same day were included. This retrospective study was approved by the Institutional Review Board of the Faculty of Medicine, Siriraj Hospital, Mahidol University, Thailand. The study was conducted according to the principles of the Declaration of Helsinki.
Magnetic Resonance Imaging
MRI examination of the liver was performed on a 3.0 T Achieva MRI scanner (Philips Medical Systems, Eindhoven, The Netherlands) using a Sense body coil (Philips Medical Systems) with the two-point Dixon without R2* (1/T2*) correction option. The sequence was a three-dimensional T1 fast-field multiecho MR sequence scanned within a breath-hold time (approximately 15 seconds) with the imaging parameters as follows: repetition time / echo time 1 / echo time 2 of 3.5 / 1.4 / 2.7 ms, respectively, matrix T h r e e c i r c u l a r r e g i o n s o f i n t e r e s t ( R O I s ) o f approximately 2.30 cm 2 were manually placed around the suspected liver biopsy area on the mid-axillary area of the liver parenchyma at the right lobe of the liver, extending from the liver capsule for about 1.0 to 1.5 inches, excluding the region of the vessels, signal artefacts, and focal fat sparing or infiltration, by a radiologist and co-localised into both water and fat images in the same liver parenchyma area. The HFF was calculated from the mean ROIs of water and fat signals on water-only and fat-only images using the following formula:
where S Fat and S Water are fat and water signals, respectively
For each patient, three HFFs were analysed and the mean was reported.
Histopathological Grading
Percutaneous liver biopsies under sonographic guidance were performed at the right lobe of the liver, located on the mid-axillary line from the liver capsule for about 1.0 to 1.5 inches with at least two usable sampling tissues in fully inspirated patients on the same day as the hepatic MRI examination by an experienced gastroenterologist. After routine processing and staining, a pathologist who specialised in the hepatobiliary system and was unaware of the patients' clinical and radiological details performed interpretation of the biopsy specimens independently. All biopsies were of an appropriate size and included enough portal tracts for confident pathological grading and staging of the histological features.
The severity of fatty infiltration, necroinflammation, and fibrosis was recorded and scored according to the schema outlined by Kleiner et al. 9 Hepatic steatosis was classified from grade 0 to 3: steatosis grade 0 (<5% macrovesicular fat in hepatocytes), grade 1 (5%-33%), grade 2 (34%-66%), and grade 3 (>66%). A diagnosis of fatty liver was made when there was steatosis of grade 1 or greater. Lobular inflammation was assessed per foci of inflammation under x 200 magnification. Grading severity of lobular and portal inflammation is shown in 
RESULTS
There were 24 patients eligible for the study, of whom three who had no available images for analysis were excluded. The mean age of the 21 patients was 47 years (range, 23-77 years) and 57% were women. The mean body mass index (BMI) was 24.6 kg/m 2 (range, 14.0-33.9 kg/m 2 ). Obesity (BMI ≥28 kg/m 2 ) was present in four (19%) of the patients. The mean value of alanine aminotransferase was 124 IU/L (range, 23-414 IU/L). Indications for liver biopsy included assessment of severity of chronic hepatitis B or C infection in 13 patients, evaluation of drug-induced hepatotoxicity in one patient, and identification of the aetiologies of chronic hepatitis in seven patients. On the basis of the histological findings, six (29%) patients were diagnosed with non-alcoholic steatohepatitis (NASH). Figure 1 shows an example of a representative ROI placement in in-phase, opposed phase, water-only, and fat-only images. The HFF of the patients included in the study are summarised in (Figure 2 ). In addition, the HFFs were significantly different among the subgroups (p < 0.05). (Table 3) .
To better understand the potential role of hepatic necroinflammation on the measurement of HFF in patients with fatty liver, we examined the relationship of the presence of steatohepatitis with the percentage of HFF (Table 3 ). The HFF of six patients with NASH was significantly higher than those of the remaining patients without NASH (p = 0.002). In addition, the HFF was higher in patients with lobular inflammation than in those without inflammation, although this did not reach statistical significance (p = 0.122). However, no significant difference of HFF was observed between patients with and without portal inflammation. 
DISCUSSION
The chemical-shift MRI, which is commonly used in clinical practice for detecting fatty changes in the liver, is limited in its inability to quantify hepatic fat content beyond a 50% fat fraction due to waterfat signal ambiguity and degrading image quality caused by susceptibility artefacts from the air-tissue interface. 4, 10 The modified chemical-shift MRI known as the mDixon sequence, which is a three-dimensional fast-field chemical-shift-based sequence using multiple echoes for water-fat separation, has a shorter scan time and provides better signal-to-noise ratio for semi-quantification of liver fat content. 7 However, the mDixon technique, based on the two-point Dixon method, might have uncorrected T2* effects, which are more often interfered with by several confounding factors such as hepatic inflammation, fibrosis, and iron deposition in the liver parenchyma. 2, 4 In patients with iron deposition and high-grade fibrosis or cirrhosis, T2* decay is an important confounding factor of the chemical-shift MRI technique and is corrected for by using the T2* correction method or the proton density fat fraction technique.
11 Our results showed significant correlation of HFF and histological grading of steatosis, particularly for the diagnosis of moderate-to-severe steatosis, with lower effects of hepatic inflammation and fibrosis on the semi-quantitation of hepatic steatosis, as there were some results that recorded no effect of fibrosis on hepatic fat quantification.
12-14 These results may be explained by the small number of patients with severe liver fibrosis (grades 3 or 4) in this study. Additionally, the measured ROIs were placed in the middle of the liver parenchyma where the susceptibility effect is less prominent than the near-hepatic diaphragm region. Nevertheless, further studies to assess the effect of T2* decay on quantification of hepatic steatosis in patients with coexisting iron deposition and the calculation of proton density fat fraction using the mDixon sequence with T2* correction are warranted.
With regard to histopathology, hepatic steatosis is defined by the accumulation of 5% or more fat in hepatocytes. Unfortunately, no exact cutoff value for MRI-measured HFF has yet been defined to discriminate between normal and abnormal levels of hepatic fat. In a study using the two-point Dixon method with MRS as the reference standard, the investigators proposed a cutoff value for HFF of 3.6% for detection of fatty liver, 8 whereas in a study using the different chemicalshift-based techniques compared with liver biopsy as the reference standard, the HFF values were reported to range from -1.46% to 2.94%. 8 Even our semiquantification of HFF using the mDixon technique is a reliable non-invasive measure, particularly for diagnosis of moderate-to-severe steatosis, we were still unable to define a cutoff point to detect the hepatic steatosis due to the small number of patients in each steatotic subgroup. The exact cutoff value of HFF in our study should be in the range of 3.37-14.91. However, the various cutoff values may be, in part, due to different MR sequences and acquisition techniques used at each centre. A larger study would more accurately determine the cutoff point between normal liver and fatty liver. The discrepancy between the MRI measurement and histopathological evaluation may be explained by the difference in targeted measurement between MRI and histopathology. MRI quantitative hepatic steatosis is calculated by the fraction of protons in lipid versus water, while the degree of steatosis in a liver biopsy specimen was interpreted based on the fraction of fatcontaining hepatocytes.
A previous study comparing paired biopsy specimens of 51 patients has reported discordance between the first and second biopsy in 22% of patients. 15 However, liver biopsy is regarded clinically as the reference standard for diagnosis of hepatic steatosis, although it may be associated with potential sampling errors. To avoid the mismatch between ROI placement and biopsy site, we performed the liver biopsy and MRI on the same day in all patients, while keeping the location target of the MRI nearly the same as the liver biopsy area, thus permitting good correlation of hepatic fat assessment. However, many causes of mismatched ROI errorssuch as respiratory, diaphragmatic, and cardiac motion as well as the selection of a safe biopsy site and size far from blood vessels -are inevitable and continue to be a concern.
Limitations of this study are the small number of patients and the unequal distribution of steatosis grading. Only two patients had steatosis grade 3 resulting in a non-statistical power difference for HFF between grade 3 steatosis and the other subgroups. A larger study is required for better assessment of the difference in HFF between each of the steatosis subgroups. Secondly, we graded histological steatosis on a discrete scale of 0 to 3, which limited the relevance of correlation with a continuous value of HFF. Histological quantification of the exact percentage of fat deposition in the hepatocytes or the semi-automatic vacuole segmentation method may be both more accurate and more valuable for further studies. Thirdly, we did not evaluate the regional heterogeneity of fat deposition in liver tissue, which became a concern for inaccurate hepatic-fat calculation because the small sample size may have been a cause of unreliable data. Finally, our study did not enrol a healthy control population and included patients with a variety of liver diseases, which is important for determining the baseline HFF of normal liver and the different underlying parameters of liver diseases that may have effects on the different patterns of fatty changes on liver parenchyma.
CONCLUSION
Semi-quantification of fat deposition in liver parenchyma using the mDixon technique is a fast and reliable method for diagnosis of hepatic steatosis, particularly for diagnosis of moderate-to-severe disease, without any interference from coexisting hepatic fibrosis or inflammation. In clinical practice, the implementation of this sequence into the routine hepatic steatosis MRI protocol could be of great benefit.
DECLARATION
No conflicts of interest were declared by authors.
